<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8563567</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">33928432</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">8563567</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">10580</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1007/s00415-021-10580-z</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical variables, mean (standard deviation)</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical variables, mean (standard deviation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">HC (<italic>N</italic> = 24)</th><th align="left">MCI-AD (<italic>N</italic> = 28)</th><th align="left">MCI-LB (<italic>N</italic> = 31)</th><th align="left">Group differences</th></tr></thead><tbody><tr><td align="left">Male:female</td><td align="left">17:7</td><td align="left">14:14</td><td align="left">29:2</td><td align="left"><p><italic>χ</italic><sup>2</sup> = 14.0, <italic>p</italic> = 0.001<sup>a</sup></p><p><italic>p</italic>(HC,MCI-AD) = 0.13</p><p><italic>p</italic>(HC,MCI-LB) = 0.02</p><p><italic>p</italic>(MCI-AD,MCI-LB) &lt; 0.001</p></td></tr><tr><td align="left">Age</td><td align="left">73.5 (7.6)</td><td align="left">76.2 (7.9)</td><td align="left">74.7 (6.6)</td><td align="left"><italic>F</italic>(2,80) = 0.9, <italic>p</italic> = 0.41<sup>b</sup></td></tr><tr><td align="left">AChEI</td><td align="left">–</td><td align="left">5 (19%)<sup>e</sup></td><td align="left">14 (47%)<sup>f</sup></td><td align="left"><italic>χ</italic><sup>2</sup> = 5.1, <italic>p</italic> = 0.08<sup>c</sup></td></tr><tr><td align="left">PD meds</td><td align="left">–</td><td align="left">0<sup>e</sup></td><td align="left">2 (7%)<sup>f</sup></td><td align="left"><italic>χ</italic><sup>2</sup> = 2.2, <italic>p</italic> = 0.32<sup>c</sup></td></tr><tr><td align="left">Years of education</td><td align="left">14.5 (3.7)<sup>g</sup></td><td align="left">12.9 (3.5)</td><td align="left">12.1 (3.0)</td><td align="left"><p><italic>F</italic>(2,77) = 3.4, <italic>p</italic> = 0.04<sup>b</sup></p><p><italic>p</italic>(HC,MCI-AD) = 0.32</p><p><italic>p</italic>(HC,MCI-LB) = 0.03</p><p><italic>p</italic>(MCI-AD,MCI-LB) = 1.0</p></td></tr><tr><td align="left">ACE-R</td><td align="left">92.3 (4.4)</td><td align="left">82.2 (8.8)</td><td align="left">83.4 (9.5)</td><td align="left"><italic>t</italic><sub>57</sub> = 0.5, <italic>p</italic> = 0.62<sup>d</sup></td></tr><tr><td align="left">MMSE</td><td align="left">28.3 (1.1)</td><td align="left">27.0 (2.2)</td><td align="left">26.6 (2.6)</td><td align="left"><italic>t</italic><sub>57</sub> = 0.6, <italic>p</italic> = 0.61<sup>d</sup></td></tr><tr><td align="left">UPDRS III</td><td align="left">5.3 (4.3)</td><td align="left">16.2 (15.1)</td><td align="left">22.8 (14.9)</td><td align="left"><italic>t</italic><sub>57</sub> = 1.7, <italic>p</italic> = 0.1<sup>d</sup></td></tr><tr><td align="left">DCFS</td><td align="left">–</td><td align="left">6.7 (1.9)<sup>h</sup></td><td align="left">8.8 (3.5)<sup>i</sup></td><td align="left"><italic>t</italic><sub>49</sub> = 2.6, <italic>p</italic> = 0.01<sup>d</sup></td></tr><tr><td align="left">CAF total</td><td align="left">–</td><td align="left">1.3 (2.4)<sup>h</sup></td><td align="left">4.2 (4.5)<sup>i</sup></td><td align="left"><italic>t</italic><sub>49</sub> = 2.8, <italic>p</italic> = 0.008<sup>d</sup></td></tr><tr><td align="left">NPI total</td><td align="left">–</td><td align="left">7.6 (8.3)<sup>h</sup></td><td align="left">14.9 (12.6)<sup>i</sup></td><td align="left"><italic>t</italic><sub>49</sub> = 2.4, <italic>p</italic> = 0.02<sup>d</sup></td></tr><tr><td align="left">NEVHI</td><td align="left">–</td><td align="left">0.6 (1.2)<sup>j</sup></td><td align="left">3.3 (4.4)</td><td align="left"><italic>t</italic><sub>56</sub> = 3.1, <italic>p</italic> = 0.003<sup>d</sup></td></tr><tr><td align="left">Mean FD (mm)</td><td align="left">0.25 (0.09)</td><td align="left">0.28 (0.10)</td><td align="left">0.26 (0.11)</td><td align="left"><italic>F</italic>(2,80) = 0.6, <italic>p</italic> = 0.59<sup>b</sup></td></tr><tr><td align="left">Max FD (mm)</td><td align="left">0.94 (0.66)</td><td align="left">1.3 (0.65)</td><td align="left">1.1 (0.73)</td><td align="left"><italic>F</italic>(2,80) = 1.7, <italic>p</italic> = 0.19<sup>b</sup></td></tr></tbody></table><table-wrap-foot><p><italic>ACE-R</italic> Addenbrooke’s Cognitive Examination—Revised, <italic>AChEI</italic> number of patients taking acetylcholinesterase inhibitors, <italic>CAF total</italic> Clinician Assessment of Fluctuation total score, <italic>DCFS</italic> Dementia cognitive fluctuation scale, <italic>FD</italic> framewise displacement, <italic>HC</italic> healthy controls, <italic>MCI-AD</italic> mild cognitive impairment with Alzheimer’s disease, <italic>MCI-LB</italic> probable mild cognitive impairment with Lewy bodies, <italic>MMSE</italic> Mini Mental State Examination, <italic>NEVHI</italic> North-East Visual Hallucinations Interview, <italic>NPI</italic> Neuropsychiatric Inventory, <italic>PD meds</italic> number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms, <italic>UPDRS III</italic> Unified Parkinson’s Disease Rating Scale III (motor subsection)</p><p><sup>a</sup>Chi-square test HC, MCI-AD, MCI-LB; <sup>b</sup>Univariate ANOVA HC, MCI-AD, MCI-LB; <sup>c</sup>Chi-square test MCI-AD, MCI-LB; <sup>d</sup>Student’s <italic>t</italic> test MCI-AD, MCI-LB, <sup>e</sup><italic>N</italic> = 26, <sup>f</sup><italic>N</italic> = 30, <sup>g</sup><italic>N</italic> = 22, <sup>h</sup><italic>N</italic> = 23, <sup>i</sup><italic>N</italic> = 28, <sup>j</sup><italic>N</italic> = 27</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical variables, mean (standard deviation)</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">HC (N = 24)</th><th align="left">MCI-AD (N = 28)</th><th align="left">MCI-LB (N = 31)</th><th align="left">Group differences</th></tr></thead><tbody><tr><td align="left">Male:female</td><td align="left">17:7</td><td align="left">14:14</td><td align="left">29:2</td><td align="left">χ2 = 14.0, p = 0.001ap(HC,MCI-AD) = 0.13p(HC,MCI-LB) = 0.02p(MCI-AD,MCI-LB) &lt; 0.001</td></tr><tr><td align="left">Age</td><td align="left">73.5 (7.6)</td><td align="left">76.2 (7.9)</td><td align="left">74.7 (6.6)</td><td align="left">F(2,80) = 0.9, p = 0.41b</td></tr><tr><td align="left">AChEI</td><td align="left">–</td><td align="left">5 (19%)e</td><td align="left">14 (47%)f</td><td align="left">χ2 = 5.1, p = 0.08c</td></tr><tr><td align="left">PD meds</td><td align="left">–</td><td align="left">0e</td><td align="left">2 (7%)f</td><td align="left">χ2 = 2.2, p = 0.32c</td></tr><tr><td align="left">Years of education</td><td align="left">14.5 (3.7)g</td><td align="left">12.9 (3.5)</td><td align="left">12.1 (3.0)</td><td align="left">F(2,77) = 3.4, p = 0.04bp(HC,MCI-AD) = 0.32p(HC,MCI-LB) = 0.03p(MCI-AD,MCI-LB) = 1.0</td></tr><tr><td align="left">ACE-R</td><td align="left">92.3 (4.4)</td><td align="left">82.2 (8.8)</td><td align="left">83.4 (9.5)</td><td align="left">t57 = 0.5, p = 0.62d</td></tr><tr><td align="left">MMSE</td><td align="left">28.3 (1.1)</td><td align="left">27.0 (2.2)</td><td align="left">26.6 (2.6)</td><td align="left">t57 = 0.6, p = 0.61d</td></tr><tr><td align="left">UPDRS III</td><td align="left">5.3 (4.3)</td><td align="left">16.2 (15.1)</td><td align="left">22.8 (14.9)</td><td align="left">t57 = 1.7, p = 0.1d</td></tr><tr><td align="left">DCFS</td><td align="left">–</td><td align="left">6.7 (1.9)h</td><td align="left">8.8 (3.5)i</td><td align="left">t49 = 2.6, p = 0.01d</td></tr><tr><td align="left">CAF total</td><td align="left">–</td><td align="left">1.3 (2.4)h</td><td align="left">4.2 (4.5)i</td><td align="left">t49 = 2.8, p = 0.008d</td></tr><tr><td align="left">NPI total</td><td align="left">–</td><td align="left">7.6 (8.3)h</td><td align="left">14.9 (12.6)i</td><td align="left">t49 = 2.4, p = 0.02d</td></tr><tr><td align="left">NEVHI</td><td align="left">–</td><td align="left">0.6 (1.2)j</td><td align="left">3.3 (4.4)</td><td align="left">t56 = 3.1, p = 0.003d</td></tr><tr><td align="left">Mean FD (mm)</td><td align="left">0.25 (0.09)</td><td align="left">0.28 (0.10)</td><td align="left">0.26 (0.11)</td><td align="left">F(2,80) = 0.6, p = 0.59b</td></tr><tr><td align="left">Max FD (mm)</td><td align="left">0.94 (0.66)</td><td align="left">1.3 (0.65)</td><td align="left">1.1 (0.73)</td><td align="left">F(2,80) = 1.7, p = 0.19b</td></tr></tbody></table></div>ACE-R Addenbrooke’s Cognitive Examination—Revised, AChEI number of patients taking acetylcholinesterase inhibitors, CAF total Clinician Assessment of Fluctuation total score, DCFS Dementia cognitive fluctuation scale, FD framewise displacement, HC healthy controls, MCI-AD mild cognitive impairment with Alzheimer’s disease, MCI-LB probable mild cognitive impairment with Lewy bodies, MMSE Mini Mental State Examination, NEVHI North-East Visual Hallucinations Interview, NPI Neuropsychiatric Inventory, PD meds number of patients taking dopaminergic medication for the management of Parkinson’s disease symptoms, UPDRS III Unified Parkinson’s Disease Rating Scale III (motor subsection)aChi-square test HC, MCI-AD, MCI-LB; bUnivariate ANOVA HC, MCI-AD, MCI-LB; cChi-square test MCI-AD, MCI-LB; dStudent’s t test MCI-AD, MCI-LB, eN = 26, fN = 30, gN = 22, hN = 23, iN = 28, jN = 27</transformed-table></extracted-table></extracted-tables-set>